secwatch.observer — SEC 8-K summary
======================================

Issuer:     ImmunityBio, Inc. (IBRX)
CIK:        0001326110
Form:       8-K
Filed at:   2025-08-08T23:59:59+00:00
Accession:  0001193125-25-177024
Event type: litigation
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud

ImmunityBio reaches preliminary settlement in shareholder derivative lawsuit
----------------------------------------------------------------------------

- Court preliminarily approved derivative settlement on July 29, 2025, with final hearing set for Nov 4, 2025.
- Settlement requires ImmunityBio to adopt corporate governance reforms including a new independent director and enhanced compliance.
- Attorneys' fees not to exceed $1.4 million will be paid by insurance; no monetary payment to shareholders.
- Governance reforms include quarterly board updates on FDA/cGMP compliance and annual legal department reviews.
- Settlement resolves derivative actions related to alleged oversight failures and misleading statements about Anktiva BLA.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1326110/000119312525177024/0001193125-25-177024-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1326110/000119312525177024/d29656d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-177024

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer